Postępy Dermatologii i Alergologii

Full text

3/2026 vol. 43
Letter to the Editor

Early and significant improvement of rupioid psoriasis with bimekizumab

  1. Department of Dermatology and Venereology, Ankara Etlik City Hospital, Ankara, Turkey

  2. Department of Pathology, Ankara Etlik City Hospital, Ankara, Turkey

Adv Dermatol Allergol 2026; XLIII (3): 330–332

Data publikacji online: 2026/07/20
Article file
PDIA Early.pdf
  1. Steele CE, Anderson M, Miedema J, Culton D. Rupioid psoriasis and psoriatic arthritis in a patient with skin of color. Cutis 2020; 106: E2-4.
  2. Diab S, Al-Janabi MH, Diab I, Hassan F. Rupioid psoriasis, a unique presentation treated with Ustekinumab. Oxf Med Case Rep 2024; 2024: omae138.
  3. Chung HJ, Marley-Kemp D, Keller M. Rupioid psoriasis and other skin diseases with rupioid manifestations. Cutis 2014; 94: 119-21.
  4. Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis 2022; 12: 127-37.
  5. Ward C, Ravichandran S, Chen WS, Albers S. Rupioid psoriasis: a complex, multifactorial presentation. J Case Rep Images Pediatr 2023; 5: 1-5.
  6. Qiu Y, Zhu Y, Liu Y, Liu Q. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials. J Dermatolog Treat 2023; 34: 2199106.
  7. Santos-Alarcón S, Mataix-Diaz FJ, Schneller-Pavelescu Apetrei CL, Belinchón-Romero I. Rapid and sustained improvement of psoriasis with Bimekizumab: a real-world case series. JEADV Clin Pract 2024; 3: 1270-3.
  8. Wang Y, Li S, Bai J, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Ther Adv Chronic Dis 2023; 14: 20406223231163110.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
without publication fees